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ABSTRACT 
Prevalence rates of epilepsy in individuals with intellectual disability (ID) are much 
higher than in the general population. Although antiepileptic drug (AED) therapy is considered 
the first line of treatment, a significant number of individuals on AEDs still do not achieve total 
seizure control. Further, many individuals experience side effects (SE) from long-term AED use. 
The assessment of AED SE in individuals with ID and epilepsy is an important aspect of 
treatment. The present study focused on the Scale for the Evaluation and Identification of 
Seizures, Epilepsy, and Anticonvulsant Side Effects-B (SEIZES-B), developed to assess SE from 
AED use in adults with ID and epilepsy. The purpose of this study was two-fold. First, the 
psychometric properties of the SEIZES-B were investigated. Interrater reliability of direct 
observations was explored using a licensed epileptologist and registered nurse as informants. 
Interrater reliability between observers was poor. The SEIZES-B was then compared to the 
epileptologists’ direct observation rating to provide an estimate of convergent validity. 
Correlational analyses were low and non-significant. Second, 45 participants were compared 
across three groups (those with epilepsy taking AEDs, those with a diagnosis of epilepsy not 
taking AEDs, and those without epilepsy taking antipsychotic medications) on SE profiles of the 
SEIZES-B. Significant differences were not found across the groups. Results and implications of 
these data are discussed. 
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INTRODCTION 
Individuals with epilepsy and intellectual disabilities (ID) often experience side effects 
(SE) from antiepileptic drug (AED) use. Despite the availability of newer AEDs associated with 
less severe SE, individuals with ID remain susceptible (Ettinger, Barr, & Solomon, 2001). 
Traditional standards for assessing SE in the general population often rely on self-report. 
Individuals with ID, however, often have communication deficits making self-report instruments 
inappropriate for this population. The first goal of this study further investigated the 
psychometric properties of The Scale for the Evaluation and Identification of Seizures, Epilepsy, 
and Anticonvulsant Side Effects-B (SEIZES-B), for the evaluation and identification of AED SE 
using third-party ratings. The second goal of this study examined SE profiles of the SEIZES-B of 
those taking AEDs, those not taking AEDs, and those without epilepsy taking antipsychotic 
medications. This study represents an essential step towards validating the use of this scale in the 
ID population and may facilitate its use in identifying SE from AED use. A brief review of ID, 
seizures and epilepsy, and those with comorbid ID and epilepsy is discussed. 
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INTELLECTUAL DISABILITY 
Definition and Classification  
Prior to the nineteenth century there was little uniformity worldwide in the description 
and classification of ID. Although ID has always been present, its definition is socially and 
politically driven (Patton & Jones, 1994; Scheerenberger, 1983). The official classification of ID 
was formulated by two organizations, the American Association on Mental Retardation (AAMR; 
1992) and the American Psychiatric Association (APA; 2000). The AAMR and APA 
classification system include three essential features of ID, including: 1) deficits in intellectual 
functioning; 2) concurrent deficits in adaptive functioning; and 3) onset before age 18. While 
these classification systems are similar on the basis of criteria used to determine ID, they differ 
in their application. For example, the AAMR definition is intended to facilitate inclusive 
education, supported or competitive employment, and supported living (MacMillian, Gresham, 
& Siperstein, 1995), whereas the Diagnostic and Statistical Manual, Fourth Edition Text 
Revision (DSM-IV-TR) specifies severity levels of ID based on standardized, individually 
administered intelligence tests (APA, 2000). 
Assessment of Intellectual Functioning 
General intellectual functioning is measured by the intelligence quotient (IQ; Eysenck, 
1962), obtained by objective, standardized, individually administered intelligence tests (e.g., 
Standford-Binet, Wechsler Intelligence Scales; APA, 2000). In 1905, the Binet-Simon Individual 
Tests of Intelligence was the first intelligence test that assessed judgment, comprehension, 
reasoning, as well as, distinguished between varying degrees of ID (i.e., idiocy, imbecility, and 
moronity; Eysenck, 1962). Currently, sub-average intellectual functioning is defined as an IQ 
score of approximately 70 or below, which are two standard deviations below the population 
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mean (Biasini, Grupe, Huffman, & Bray, 2001). Until 1960, sub-average intelligence was 
considered the sole criteria for ID classification according to the AAMR (AAMR, 1992). In 
1961, the AAMR redefined ID to also include limitations in adaptive functioning and onset 
before age 18 (Patton & Jones, 1994).  
One of the major problems in applying conventional intelligence tests to the ID 
population is that these individuals may be influenced by additional deficits such as lack of 
motivation to comply with testing, thus making it difficult or impossible to use the available 
instruments and testing protocols (Beirne-Smith, Ittenbach, & Patton, 1994). Another criticism in 
applying conventional intelligence tests to this population is that intelligence tests measure a 
limited range of intellectual abilities. There are other abilities such as adaptive behavior, which 
rely on everyday (i.e., social and practical) intelligence that cannot be estimated accurately by 
standardized intelligence tests (Patton & Jones, 1994). To this end, adaptive functioning has 
become an important and necessary accessory to any diagnostic standard for ID (Greenspan, 
Switzsky, & Granfield, 1996). 
Assessment of Adaptive Functioning 
Assessment of adaptive behavior focuses on how well an individual can function 
independently and meet the social and practical demands imposed on the individual by their 
culture (Beirne-Smith, Patton, & Ittenbach, 1994). According to the DSM-IV-TR, criteria is met 
when deficits in at least two of the following 10 areas has been demonstrated: communication, 
social skills, self-care, home living, use of community resources, self-direction, health and 
safety, functional academics, leisure, and work (APA, 2000). Although there are numerous 
adaptive behavior scales, the most commonly used scale is the Vineland Adaptive Behavior 
Scales (VABS; Sparrow, Balla, & Cicchetti, 1984). The VABS was designed to assess 
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handicapped and non-handicapped persons from birth to adulthood in their personal and social 
functioning. The VABS is organized around four behavior domains: communication, daily living 
skills, socialization, and motor skills (Doll, 1953). The utility of adaptive instruments for 
identifying persons with ID has been debated because domains such as leisure, work, and use of 
community resources are difficult to define and measure (Zigler, Balla, & Hodapp, 1984). On the 
other hand, adaptive scales used in conjunction with other standardized assessments provide 
valuable information regarding communication, social skills, and daily living which can be 
useful in treatment planning (Greenspan, Switzsky, & Granfield, 1996). 
 The last criterion for a diagnosis of ID is onset before age 18 (AAMR, 1992; APA, 
2000). For example, many chromosomal abnormalities associated with more severe levels of ID 
such fragile X syndrome or Down’s syndrome is diagnosed during pregnancy or infancy 
(Dykens, Hodapp, & Fincucane, 2000). Milder levels of ID tend to be diagnosed in early 
childhood whereas ID with an unknown etiology is usually diagnosed later in childhood 
(Alexander, 1998).  
Characteristics of Intellectual Disability 
The current criteria used to differentiate severity levels of ID are associated with ranges 
of IQ scores. According to the DSM-IV-TR criteria, severity levels of ID are divided as follows: 
Mild (IQ level 50-55 to 70-75); Moderate (IQ level 35-40 to 50-55); Severe (IQ level 20-25 to 
35-40); Profound (IQ level below 20 or 25); and Severity Unspecified (strong presumption of ID 
but the individual cannot be successfully tested by standardized intelligence tests).  
The Mild group comprises about 85% of those classified as ID (APA, 2000). These 
individuals are often not physically distinguishable from those without ID. During infancy and 
early childhood, those with mild ID may have minimal impairment in social, communication 
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skills and sensorimotor functioning. By their late teens, learning difficulties may emerge in their 
academic work. During adulthood, these individuals typically live successfully in the community 
with minimal assistance, although some guidance may be necessary during stressful situations 
such as economic hardships (Harris, 1995). 
The Moderate group comprises approximately 10% of those classified as ID (APA, 
2000). Language development, social interactions, and communication skills vary across this 
group. Some have the capacity to have simple conversations while others have limited 
communication of basic needs (APA, 2000). These individuals also have limitations in their 
achievement of self-care and motor skills into adulthood. These individuals typically need 
supportive employment programs, supported workshops, and live in community-based group 
homes (Harris, 1995). 
The Severe group comprises approximately 3% to 4% of the ID population (APA, 2000). 
These individuals typically have marked motor impairment and other associated deficits in 
language, communication, and self-care. These individuals typically need supervision in task 
performance in group homes or community programs (Harris, 1995). 
The Profound group comprises approximately 1% to 2% of the ID population (APA, 
2000). These individuals typically have neurological and physical disabilities that impair 
sensorimotor functioning and language comprehension. They may have limited understanding of 
simple verbal instructions and often require continual assistance with self-care. These individuals 
usually benefit from highly structured environments, such as developmental centers (Harris, 
1995).  
Lastly, the Severity Unspecified category is reserved for cases where there is a 
presumption of ID, but IQ values are unobtainable because the individual cannot be assessed by 
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standard tests. This may occur when children, adolescents, and adults are uncooperative or too 
impaired to participate in standardized testing (APA, 2000). These individuals typically have 
physical and sensory disabilities, such as blindness, deafness, and/or severe behavioral deficits 
(Harris, 1995). 
Etiology of Intellectual Disability 
The etiology of ID is based either on identifying a causative agent or a specific 
mechanism usually diagnosed in infancy or childhood (Harris, 1995). For example, many 
chromosomal abnormalities, including fragile X syndrome and Down’s syndrome can be 
definitively diagnosed during pregnancy by chromosome analysis (Dykens, Hodapp, & 
Finucane, 2000). Developmental errors or teratogenic factors during prenatal, perinatal, and 
postnatal periods may increase the likelihood of developing ID (Alexander, 1998).  
Developmental abnormalities during prenatal periods include chromosomal disorders, 
syndrome disorders, inborn errors of metabolism, and developmental disorders of brain 
formation. Elevated levels of alpha-fetoprotein for example, may increase the risk for neural tube 
defects and trisomy chromosomal aberrations during gestation (Crocker, 1992). In approximately 
20% to 30% of those with severe ID, the cause has been attributed to prenatal factors (Dykens, 
Hodapp, & Finucane, 2000). 
Developmental problems during perinatal periods may include intrauterine disorders and 
neonatal disorders. Perinatal factors such as hypoxia, hydrocephalus, and neonatal seizures 
account for approximately 11% of those with severe ID (Bernes & Kaplan, 1994). Lastly, 
postnatal causes typically include head injuries, infections, degenerative disorders, seizure 
disorders, toxic metabolic disorders, malnutrition, and environmental deprivation (Harris, 1995). 
Exposure to environmental toxins, such as lead and mercury, account for approximately 3% to 
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12% of those with severe ID (Dykens, Hodapp, & Finucane, 2000). Conversely, it has been 
estimated that between 45% and 63% of mild ID cases are attributed to unknown causes, and 
very few postnatal causes have been associated with mild ID (McLaren & Bryson, 1987).   
Prevalence of Intellectual Disability 
 Over the past 100 years the prevalence of ID has been affected by changes in diagnostic 
criteria, empirical sampling, and improvements in medical care and technology (Sheerenberger, 
1983). Based on empirical sampling, Baroff (1991) has suggested that only 0.9% of the 
population can be assumed to have ID. Following a review of epidemiological studies, McLaren 
and Bryson (1987) reported that the prevalence of ID was around 1.25% of the total population.    
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SEIZURES AND EPILEPSY 
Classification and Diagnosis 
 Though there have always been people with seizures and epilepsy, the modern medical 
era of epileptology began during the late 19th century. A British neurologist, John Hughlings 
Jackson, defined seizures as an “occasioning, excessive and disorderly discharge of nerve tissue 
on muscles” and recognized their effect on consciousness, sensation, and behavior (Jackson, 
1890, p. 703). Prior to 1929, diagnostic measures of seizure activity and epilepsy lacked 
reliability and validity, and relied heavily on direct observation. However, in 1929 technological 
advances allowed for concurrent electroencephalogy and filming of patient behavior. More 
recently, simultaneous EEG telemetry and video of concurrent behavior has refined our 
knowledge of the relationship between epileptiform abnormalities and observed behavior 
(Gastaut, 1970; Sundaram, Sadler, Young, & Pillay, 1999). Technology has greatly advanced the 
ability of medical professionals to identify and differentially diagnose neurological deficits; 
EEGs are now considered the gold standard among criteria for diagnosing epilepsy (Cuthill & 
Espie, 2005). 
 The most widely accepted classification system of seizure types and epileptic syndromes 
that is currently used is the International Classification of Epilepsies and Epileptic Syndromes 
(ICES). This classification system, proposed by the Commission on Classification and 
Terminology of the International League Against Epilepsy (ILEA) in 1989, defines an ictus (i.e., 
seizure) as a sudden neurological occurrence. Epilepsy is defined as a chronic neurological 
condition characterized by recurrent epileptic seizures (Gastaut, 1973). Epilepsy is differentiated 
from incidental seizures in that epilepsy is a chronic, long-lasting condition of at least two or 
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more seizures and predisposes individuals to have more seizures (Adams, Victor, & Ropper, 
1997).  
 Epileptic seizures can be classified according to their etiology, clinical manifestation, and 
anatomic focus or source of origin. Epilepsy syndromes are defined by a cluster of features that 
include, but are not limited to, seizure type, age of onset, heredity of seizures, EEG findings, 
comorbid conditions, response to treatment, and prognosis for seizure control and remission 
(Coulter, 1993). In medical literature, seizures are typically classified into two types: generalized 
and partial (Wyllie, 1993). 
Generalized Seizures 
Generalized seizures usually have a unilateral focus that spreads to become generalized. 
These seizures are accompanied by a widespread electrical discharge involving both 
hemispheres. They are typically divided into tonic-clonic seizures, absence seizures, and other 
generalized seizures. Generalized tonic-clonic seizures are the most common epileptic 
manifestation of childhood neurological diseases (Holmes, 1997). These seizures typically 
involve somatosensory auras that may include visual, auditory, olfactory, and gustatory 
experiences prior to the onset of a seizure (Tuxhorn, 2005). During a tonic-clonic seizure, 
stiffening of extremities (tonic phase), rhythmic jerking of an extremity or the whole body 
(clonic phase), and loss of consciousness occur (Trimble, Ring, & Schmitz, 2000). 
The second type of generalized seizures, absence seizures, are subtler than tonic-clonic 
seizures because they occur suddenly and are often mistaken for daydreaming. These individuals 
may appear to have a blank facial expression, suffer from loss of consciousness, and may have 
automatisms in the form of lip smacking, licking, chewing, and finger movements (Tuxhorn, 
2005). Subtypes of absence seizures include typical and atypical. Typical absence seizures are 
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often very brief and involve loss of consciousness only. In contrast, atypical absence seizures last 
longer and may involve tonic, clonic, or automatic movements (Holmes, 1997). Although 
atypical absence seizures are characteristically similar to absence seizures, they are often 
associated with other types of seizures and are typically more difficult to control with 
antiepileptic medications (Schiff, Labar, & Victor, 1999). 
Other generalized seizures include tonic, clonic, myoclonic, and atonic seizures. These 
seizures represent the least common types of generalized seizures (Adams, Victor, & Ropper, 
1997). Unlike tonic-clonic seizures, tonic and clonic seizures occur independently but have 
tonic-clonic features such as loss of consciousness (Trimble, Ring, & Schmitz, 2000). Myoclonic 
and atonic seizures are differentiated from tonic and clonic seizures because loss of 
consciousness does not occur during these episodes (Mangano, Fontana, & Cusumano, 2005). 
Myoclonic seizures are characterized by single or repetitive contractions of a muscle or group of 
muscles, whereas atonic seizures are characterized by sudden, momentary loss of posture or 
muscle tone. Generalized myoclonic, atonic, and tonic seizures are all features of the Lennox-
Gastaut syndrome common in the ID population. The Lennox-Gastaut syndrome is defined as the 
presence of slow-spike wave complexes in individuals with tonic seizures and more than one 
other seizure type (Aicardi & Gomes, 1988). 
Partial Seizures 
Unlike generalized seizures, partial seizures begin in a specific area of one cerebral 
hemisphere and do not spread bilaterally (Holmes, 1997). Partial seizures, which are associated 
with lesions of the temporal lobe (Schiff, Labar, & Victor, 1999), are subdivided into simple 
partial seizures (in which consciousness retained); and complex partial seizures (in which 
consciousness is impaired or lost)  (Kotagal, Rothner, Erenberg, Cruse, & Wyllie, 1987). Both 
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simple and complex partial seizures are often accompanied by somatosensory auras, including 
complex visual or auditory hallucinations (Janszky, Schulz, & Ebner, 2004). Additionally, partial 
seizures may spread to cause a generalized seizure, in which case the classification category is 
partial seizures secondary generalized (Holmes, 1997).  
Etiology of Epilepsy 
According to the ICES (1989), there are three etiological classifications of epilepsy. 
These etiological classifications include confirmed, suspected, and unknown. Potential factors 
leading to the presence of epilepsy include a genetic predisposition, alternations in neuronal and 
neurotransmitter metabolism, electrophysiological abnormalities, and neuropathic changes 
(Adams, Victor, & Ropper, 1997). Additionally, there are certain etiological factors associated 
with age of onset. More specifically, in infancy and early childhood, chromosomal abnormalities, 
congenital disorders, metabolic disorders, and brain infections (e.g., encephalitis, meningitis), are 
considered to be the most common etiological factor (Okumura et al., 2000). In young adults, 
head trauma and brain tumors are the most common cause of seizures. In older adults, comorbid 
physical and neurological conditions (e.g., cerebrovascular disease, degenerative disease) are the 
most common cause (Gareri, Gravina, Ferreri, & De Sarro, 1999). Although numerous causes of 
epilepsy are known, it has been estimated that underlying causes of epilepsy is unknown in up to 
50% of cases (Wyllie, 1993).  
Prevalence of Epilepsy 
 Given the complex nature of classifying and diagnosing seizures and epilepsy, it is not 
surprising that prevalence rates vary. Possible explanations for this phenomenon include newly 
diagnosed cases of unprovoked seizures, the utilization of various diagnostic criteria in 
experimental settings, and lack of standardized definitions of seizure control (Mohanraj & 
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Brodie, 2005). Nevertheless, Hauser and Hesdorffer (1990) estimate that epilepsy affects 
approximately 1% to 3% of the general population. Further, these researchers suggest that 
approximately 1% of persons within the United States will have epilepsy by the age of 20.  
Prognosis 
 Treatment outcome depends on the etiology of the epilepsy, the frequency, intensity, 
duration, and type of seizures. Seizures with particularly bad prognostic features include epilepsy 
associated with congenital neurological deficits, progressive neurological disorder, suspected or 
unknown etiology, partial epilepsies, and those with Lennox-Gastaut syndrome (Berg et al., 
2001; Drislane & Schomer, 1994; Rantakallio, von Wendt, & Koivu, 1987). All of these 
conditions have particularly high associations with ID (Chevrie & Aicardi, 1978; Lennox, 1960; 
Koo & Holmes, 1999; Okumura, 2000; Yamanouchi et al., 2005). 
Treatments 
 There are two types of treatments available for epilepsy: pharmacological and surgical. 
The first line of epilepsy treatment is pharmacological. This typically includes an AED regimen 
and therapeutic drug monitoring via laboratory testing of blood levels (Patil & Bodhankar, 2005; 
Specht, Elsner, May, Schimichowski, & Thorbecke, 2003). However, those who do not achieve 
satisfactory seizure control despite adherence to pharmacological interventions (i.e., refractory 
epilepsy) are often considered candidates for specific surgical interventions. Characteristics of 
good candidates for brain surgery include those with a distinct epileptic focus in a surgically 
removable area of the brain (e.g., lobectomy, hemispherectomy). Individuals with additive 
handicaps such as ID or multi-epileptic foci are often considered to be poor candidates for brain 
surgery (Wilfong, 2002). However, in individuals with refractory epilepsy and where removal of 
brain tissue is not feasible, these individuals are sometimes considered for vagal nerve 
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stimulation (VNS) surgery (Andriola & Vitale, 2001). The vagal nerve stimulator is an electrode 
that is surgically implanted around the left vagus nerve and normalizes electrical pulses to the 
brain (Gates, Huf, & Frost, 2001). The normalization of neuronal activity mitigates the frequency 
and severity of seizures in some individuals (Huf, Mamelak, & Kneedy-Cayem, 2005).  
Pharmacological Treatment 
 Antiepileptic drugs are traditionally used in the treatment of epilepsy. There are two 
families of AEDs: classic and newer. Classic AEDs include phenobarbital, phenytoin, primidone, 
ethnosuximide, carbamazepine, benzodiazepines, and valproate (Herranz, Armijo, & Arteaga, 
1988). Newer AEDs, which include oxcarbazepine, gabapentin, lamotrigine, and sabril, 
reportedly have less toxicity than classic AEDs with respect to the central nervous system (CNS; 
Harden, 1997). 
 Based on their psychotropic properties and mechanisms of action, classic and newer 
AEDs are generally classified as sedating or activating (McDonnell & Morrow, 1996). Sedating 
AEDs (e.g., barbiturates, benzodiazepines, valproic acid, gabapentin, tiagabine, and vigabatrin) 
are associated with fatigue, cognitive slowing, and possible anxiolytic and antimanic effects. 
These actions may be related to a predominance of potentiation of y-adminobutyric acid 
(GABA) inhibitory neurotransmission (Ketter, Post, & Theodore, 1999). Activating AEDs (e.g., 
felbamate and lamotrigine) have possible anxiogenic and antidepressant effects, such as 
agitation, aggression, irritability, and hyperactivity, and are associated with attenuation of 
glutamate excitatory neurotransmission (Reijs, Aldenkamp, & De Krom, 2004).  
 Although significant pharmacological advances have been made in the treatment of 
epilepsy, it is evident that none of the major AEDs are free from untoward side effects (SE; 
Brodie, 2001). There are generally five domains of SE individuals experience from AED use. 
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These domains include cognition, mood, behavior, motor, and physical effects (Gates, 2000; 
Glauser, 2004; Reijs, Aldenkamp & Krom, 2004). The most common SE of cognitive 
impairments includes decreased performance on intelligence tests, memory, attention, confusion, 
and processing speed (Drane & Meador, 2002). Side effects associated with both classic and 
newer AEDs include dizziness, abnormal vision, ataxia, tremors, hepatic toxicity, nausea, 
vomiting, gastrointestinal problems, alopecia, rash, and weight changes (Buchanan, 1992; 
Carpay, Aldenkamp, & van Donselaar, 2005).  
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INTELLECTUAL DISABILITY AND EPILEPSY 
Classification and Diagnosis 
Similar to the diagnosis of epilepsy in the general population, a diagnosis of epilepsy in 
individuals with ID is based on patient history information (Richardsson, Koller, & Katz, 1981). 
Oftentimes the causative agent of ID is considered when diagnosing epilepsy in this population, 
as they often have a common etiology (Coulter, 1993). For example, prevalence studies indicate 
that 5% to 50% of individuals with mild and moderate ID have epilepsy and 30% to 70% with 
severe and profound ID have epilepsy (Coulter, 1993; Marcus, 1993; Pellock & Hunt, 1996). It is 
well established that there is a significant positive correlation between the incidence of epilepsy 
and severity of ID (Heller, 1969; Ieshima & Takeshita, 1988; Kumada et al., 2005; Marcus, 
1993). For example, in a study of 1479 children and adults, Forsgren and colleagues (1990) 
found that 299 patients had comorbid ID and epilepsy. Of the 299 patients with ID and epilepsy, 
14% had mild ID, 20.4% had moderate ID, 34.8% had severe ID, and 30.8% had profound ID. 
However, an important consideration is that reported rates differ between researchers. 
Prevalence of Intellectual Disability and Epilepsy 
Prevalence rates of epilepsy are much higher in children and adults with ID than in the 
general population (Corbett, Harris, & Robinson, 1975; Forsgren, Edvinsson, Blomquist, 
Heijbel, & Sidenvall, 1990; Ieshima & Takeshita, 1988; Kumada et al., 2005; McDermott, 
Moran, & Platt, 2005; Pary, 1993). Currently, the cumulative risk of epilepsy increases 
substantially in persons with ID if there are any co-morbid conditions such as cerebral palsy, 
movement disorders, cerebral injury, and degenerative CNS diseases (Amano et al., 2000; Cole, 
2002; Goulden, Shinnar, Koller, Katz, & Richardson, 1991; Mariani, Gerini-Strambi, Sala, 
Erminio, & Smirne, 1993). Other risk factors for epilepsy in older-onset cases include 
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individuals with Down’s syndrome, those with vascular disease, brain tumors, Alzheimer’s 
syndrome, and multiple sclerosis (Wyllie, 1993). 
In fact, rates of epilepsy have been estimated to be approximately 40% to 60% in 
institutionalized ID populations (Mattson, 1996). This increased rate is due to the fact that many 
individuals with ID have comorbid neurological disorders, as well as epilepsy. For example, 
approximately three to six children per 1000 births are afflicted with cerebral palsy, moderate or 
severe ID, or both (Steffenburg, Hagberg, &Kyllerman, 1996). Moreover, it has been estimated 
that one third of those with ID and cerebral palsy have epilepsy (Richardsson, Koller, & Katz, 
1981).  
Pharmacological Treatment 
 In the past decade there has been an emphasis on polypharmacy reduction and a shift 
from using classic AEDs to newer AEDs in the ID population (Bourgeois, 2001; Bennet, 
Dunlop, & Ziring, 1983; Ettinger, Barr, & Solomon, 2001; Kelly, Stephen, & Brodie, 2004; 
Mattson, 1996; Pellock & Hunt, 1996; Poindexter, Berglund, & Kolstoe, 1993). Research has 
shown that newer AEDs are better tolerated in those with ID and multiple handicaps (Pellock, 
2002; Perucca, Beghi, Dulac, Shorvon, & Tomson, 2000). Despite this, polytherapy and classic 
AED use are still common practice in institutionalized ID populations because withdrawal of 
these drugs after long-term exposure may cause an increase in seizures (Genton, 2000; 
Goeckner, Rosenfeld, & Weber, 1995) or unmanageable behavior (Baumeister & Sevin, 1990; 
Clarke, Kelley, Thinn, & Corbett, 1990; Kerr, 2002; Matson et al., 2000), even when appropriate 
AEDs are prescribed and blood levels are in their therapeutic ranges (Patil & Bodhankar, 2005; 
Specht, Elsner, May, Schimichowski, & Thorbecke, 2003). For example, Pellock and Hunt 
(1996) conducted an open 10-year study with 244 individuals with ID and epilepsy. These 
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researchers found that in this sample the most frequently administered AEDs were phenobarbital 
(69%), phenytoin (21%), primidone (8%), and carbamazepine (1%). Similar patterns of AED use 
have been documented in other studies (Matson, Mayville, & Bamburg, 2001; Mattson, 1996; 
Pellock, 2002).  
Barbiturates  
Barbiturates are generalized CNS depressants and have historically been regarded as the 
first choice in treating recurrent seizures (Porter & Melldrum, 1990). Common barbiturates 
include phenobarbital and primidone and are used to treat generalized tonic-clonic seizures and 
partial seizures (Vinning, Carpenter, & Aman, 1999; Pellock, 2002). Phenobarbital and 
primidone modulates GABA at the postsynaptic receptor (Porter & Meldrum, 1990). Common 
SE of phenobarbital and primidone include sedation, rash, ataxia, and disturbances of cognition, 
mood, and behavior (Rogvi-Hansen & Gram, 1995; DeToledo, Lowe, & Haddad, 2002; Pellock 
& Hunt, 1996). Phenobarbital also induces hepatic microsomal metabolism; thus, the likelihood 
for drug interactions is extremely high when it is used as co-therapy (Patsalos & Perucca, 2003). 
One of the most commonly reported SE in the general population is drowsiness (Harbord, 2000). 
Although barbiturates have sedating effects, hyperactivity and irritability are frequently observed 
in those with ID (Glauser, 2004; Goeckner, Rosenfeld, & Weber, 1995; Pellock, 2002). Given 
the severity of these SE in the ID population, barbiturates are becoming less frequently used and 
are generally reserved for those with refractory epilepsy (Pellock, 2002). 
Phenytoin 
Historically, phenytoin has been a first-line medication for the prevention of tonic-clonic 
seizures, partial seizures, and acute seizure management (i.e., status epilepticus) (Pellock, 2002). 
Phenytoin blocks sustained high-frequency repetitive firing of action potentials by altering 
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sodium, potassium, and calcium conduction of membrane potentials (Porter & Meldrum, 1990). 
Unlike phenobarbital, phenytoin is one of the best-tolerated AEDs in the general population and 
does not have sedative effects (Porter & Meldrum, 1990). In the ID population however, serious 
neurological damage has been associated with phenytoin, such as deterioration of cognitive 
functioning and ataxia (Iivanainen, 1998). In addition, Matson et al., (2004) found that phenytoin 
use was associated with significant deficits in social skills in the ID population. Less serious SE 
of phenytoin includes cosmetic SE, such as gingival hyperplasia and hirsutism, which are more 
prevalent after chronic administration, higher doses, and polypharmacy (Buchanan, 1992; 
Pellock, 2002).  
Carbamazepine 
Carbamazepine has gained acceptance as a first-line treatment for tonic-clonic seizures, 
partial seizures (Waisburg & Alvarez, 1998), and secondary generalized seizures in those with 
ID, as well as comorbid psychiatric disease (Kanner, 2002; Pellock, 2002). The mechanism of 
action is similar to phenytoin, it acts pre-synaptically to decrease synaptic transmission but does 
not influence GABA uptake (Porter & Meldrum, 1990). Side effects of carbamazepine are 
similar to that of phenytoin (Herranz, Armijo, & Arteaga, 1988), including drowsiness, 
irritability, nausea and vomiting, nystagmus, and hepatic failure (Gates, 2000). However, due to 
its minimal SE on cognition and behavior, carbamazepine is widely used in persons with ID 
(Alvarez, Besag, & Iivanainen, 1998; Matson, Luke, & Mayville, 2004). 
Valproate 
Valproate, in the form of valproic acid or salt, is a broad-spectrum AED. It reduces the 
incidence and severity of tonic–clonic, absence, myoclonic, and partial seizures. It is frequently 
used in the ID population because those with one or more seizure type are often responsive to 
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valproate and suffer from relatively few SE with respect to cognition and behavior (Friis, 1998). 
Like phenytoin and carbamazepine, valproate blocks high-frequency repetitive firing of neurons 
at therapeutically relevant concentrations (Porter & Meldrum, 1990). Common SE include 
weight gain, tremor, hyperactivity, drowsiness, alopecia, and gastrointestinal upset (Buchanan, 
1992; Gates, 2000). Although valproate may have moderate SE in some individuals, it continues 
to be administered in the ID population because of its efficacy against refractory epilepsy and its 
utility in mitigating comorbid behavioral aberrations such as impulsive-aggressive behavior 
(Gates, 2000; Pellock, 2002; Rutecki & Gidal, 2002).  
Benzodiazepines  
 Benzodiazepines are used primarily for status epilepticus and refractory epilepsy, which 
are common in the ID population (Lombroso, 1983; Pellock, 2002). There are six 
benzodiazepines that include clonazepam, lorazepam, and diazepam, clorazepate, midazolam, 
nitrazepam, and clobazam. Clonazepam and clorazepate are used for chronic treatment, whereas 
diazepam is used in the treatment of status epilepticus. Clonazepam is also used for absence, 
myoclonic, and atonic seizures where control with other drugs is difficult (Vinning, Carpenter, & 
Aman, 1990). All benzodiazepines have sedative properties that include drowsiness, somnolence, 
and fatigue (Gates, 2000). Benzodiazepines are generally not preferred because of the relatively 
high frequency of SE on cognition, mood, and behavior (Wyllie, 1993). 
Lamotrigine  
 Lamotrigine has been indicated for treatment of generalized tonic-clonic seizures and 
partial seizures. Lamotrigine inhibits glutamate and aspartate release, blocks sodium channels, 
and prevents repetitive firing or neurons. It is chemically unrelated to other AEDs and is 
therefore commonly used as adjunctive therapy in adults. However, individuals with ID treated 
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with lamotrigine are at risk of experiencing Sturge-Johnson syndrome, a severe rash that can be 
irritating or fatal when combined with valproate (McKee et al., 2003). Other less severe SE from 
lamotrigine includes dizziness, headache, ataxia, somnolence, and hematologic abnormalities 
(Kustra et al., 2005).  
Assessment of Antiepileptic Side Effects 
Susceptibility to SE is inherent in all medications, especially in populations that 
experience long-term use (Clarke, Kelley, Thinn, & Corbett, 1990; Stein & Strickland, 1998). It 
has been estimated that approximately 25% to 30% of those with epilepsy in the general 
population will experience a recurrence of seizures despite appropriately prescribed medications 
and blood levels in therapeutic ranges (Patil & Bodhankar, 2005; Specht, Elsner, May, 
Schimichowski, & Thorbecke, 2003). This recurrence rate is even greater (i.e., 40%) in those 
with multiple handicaps, including ID (Singh & Towle, 1993). As a result, individuals with ID, 
especially those in institutionalized environments often experience long-term AED use because 
withdrawal from these drugs has been shown to increase seizures (Alvarez, Besag, Iivanainen, 
1998; Pellock & Morton, 2000).  
Despite the long history of AED availability and research on their efficacy, individual 
differences in clinical response and inconsistent research methodologies confound efforts to 
achieve a broad consensus regarding their psychoactive effects (Brodie, 2001; Chadwick, 1997; 
Harbord, 2000; McDonnell & Morrow, 1996; Meldrum, 2002; Mohanraj & Brodie, 2005; 
Perucca, 2002; Stein & Strickland, 1998). Selecting a specific AED for seizure treatment in those 
with ID requires a balance of the drug’s likely efficacy for both seizures and comorbid disorders 
and minimizing SE (Perucca et al., 2000). In both the general and ID population, SE may be 
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tolerated or heightened, producing toxicity that may require dosage reductions (Alvarez, Besag, 
& Iivanainen, 1998; Matson, Mayville, & Bamburg, 2001; McKee, et al., 2003).  
Assessing SE of AEDs in the ID population, however, poses considerable challenges not 
experienced in the general population (Alvarez, 1989). For example, information used to assess 
SE of AEDs in individuals with epilepsy is typically gathered by self-report, interviews, and 
direct observations (Mayville & Matson, 2004). However, individuals with ID and epilepsy 
generally have significant cognitive deficits and are frequently non-verbal, thus making self-
report measures or interviews with the patient ratings inappropriate. These factors contribute to 
the complexity of assessment, treatment, and monitoring of SE in this population (Matson, 
Bielecki, Mayville, & Matson, 2003).  
Given the limitations of patient self-report with this population, informant-based ratings 
scales, direct observations, and laboratory monitoring have become the primary method of 
assessing seizure activity and SE in these individuals (Mayville & Matson, 2004). Although 
some standardized measures on SE of AEDs in the general population exist (Kane, Lee, Bryant-
Comstock, & Gilliam, 1996), research on SE of AEDs in institutionalized ID population is sparse 
and lacks systematic, reliable, and valid measures (Matson et al., 2000; Mayville & Matson, 
2004). However, a recent study assessing the reliability of the SEIZES-B, designed to measure 
SE specific to AED use in the adult ID population, indicated moderately high overall inter-rater 
reliability (r = .72) and moderately high overall test-retest reliability (r = .63) (Matson, Laud, 
González, Malone, & Swender, 2005). The SEIZES-B scale addresses observable SE, as 
opposed to other scales that estimate subjective ratings of SE such as quality of life. The current 
study aims to further examine the psychometric properties of the SEIZES-B.  
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STUDY ONE 
Rationale 
Presently, there is a lack of research on standardized measures assessing SE of AEDs in 
individuals with ID and epilepsy. To date, no research has been conducted on the convergent 
validity of two measures assessing SE of AEDs in this population. Since this population is 
medically fragile, standardized measures assessing SE of AEDs are needed. Effectively 
monitoring SE of AEDs may allow medical professionals to adjust dosages, especially when 
multiple medications are in use. The purpose of this study was to further investigate the 
psychometric properties of the SEIZES-B. The current study’s purpose had two goals. First, 
interrater reliability of direct observations using the Pinecrest Developmental Center (PDC) 
Nursing Assessment Form was explored. A licensed epileptologist and registered nurse served as 
the observers. Second, as direct observations and third-party report are the gold standards 
available for this population (Cramer & Mattson, 1993; Mayville & Matson, 2004), the 
epileptologist’s direct observation ratings from the PDC Nursing Assessment Form was the 
standard against which the SEIZES-B was compared. This comparison served as a measure of 
convergent validity.  
Method 
Participants 
Participants were resident patients of PDC in central Louisiana. PDC is a state-run 
residential community that provides 24-hour care to approximately 550 individuals with varying 
levels of ID, ages, genders, and races. An on-site licensed psychologist or board certified 
psychiatrist diagnosed all participants with ID based on DSM-IV-TR criteria (e.g., deficits in 
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intellectual and adaptive functioning before 18 years of age). Approval from the PDC 
Institutional Review Board (IRB) was obtained prior to data collection.     
A power analysis was conducted to determine the sample size of the group required for 
the present study. The recommended level of power was set at .80, because alpha (α) or the 
predetermined level of significance was set at .05 (Cohen, 1988). Using GPOWER (Faul, & 
Erdfelder, 1992), a statistical program for determining power levels, it was determined that a 
total sample of 82 participants would be required to obtain significance for variance-based 
statistics at the .05 level. 
Seventy nine individuals with varying levels of ID were recruited for inclusion in this 
study. During the course of data collection, six participants were removed from data analysis due 
to missing Nursing Assessment Form ratings from the epileptologist, leaving 73 participants. 
Participants included 43 males and 30 females diagnosed with mild (n = 1), moderate (n = 1), 
severe (n = 11), profound (n = 59), and unspecified (n = 1) ID. Of these participants, the majority 
were Caucasian (n = 51), with a smaller sub-sample of African Americans (n = 21), and a small 
sample identified as other (n = 1). Participants’ ages ranged from 25 to 89 years, with an average 
age of 49 years. Demographic information is presented in Table 1. 
Diagnosis of epilepsy was made by a consulting licensed neurologist who reviewed 
patient medical histories prior to data collection. Classification of seizure type, determined by the 
neurologist, was based on the ILEA criteria, clinical description of seizure activity, EEG pattern, 
and additional medical information (e.g., family history, age of onset, prior neurological trauma). 
Individuals who were excluded from participating in this study were those with: 1) non-epileptic 
seizures and, 2) no seizure activity for the past two years.  
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Table 1 
Demographic Characteristics of Participants 
______________________________________________________________________________ 
Characteristic        n   % 
______________________________________________________________________________ 
 
Age at time of survey (years)    
0-21        1   1.4 
22-45        32   44.5 
46-65        31   43.1 
66+        9   12.3 
Gender   
 Female       43   58.9 
 Male        30   41.1 
Race 
Caucasian       51   69.9  
 African American      21   28.8 
 Other        1   1.4 
Level of Mental Retardation 
 
Mild        1   1.4 
 Moderate       1   1.4 
 Severe        11   15.1 
 Profound       59   80.8 
 Unspecified       1   1.4 
______________________________________________________________________________ 
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Of the 73 participants with ID and epilepsy, five seizure types were noted in the sample. 
The majority of the participants had partial epilepsy (n = 56), with 11 evolving into generalized 
seizures (i.e., partial seizures secondary generalized). Other seizure types included generalized (n 
= 6), Lennox-Gastaut (n = 7), and epilepsy NOS (n = 4). These diagnoses were noted during the 
chart review and are listed in Table 2.   
Table 2 
Classification of Seizure Types 
______________________________________________________________________________ 
Classification        n   % 
______________________________________________________________________________ 
 
Generalized        6   8.2 
 
Partial         45   61.6 
Partial seizures secondary generalized    11   15.1 
Lennox-Gastaut       7   9.6 
Epilepsy NOS        4   5.5 
______________________________________________________________________________ 
 
Since dosage and regimen of medications may have an impact on the presence and 
severity of SE, current medication use was noted during the participants’ chart review. All 
participants were on at least one AED at the time of review. Twenty seven participants (37%) 
were on one AED, 29 participants (39.7%) were on two AEDs, 16 participants (21.9%) were on 
three AEDs, and one participant (1.4%) was on four AEDs. Overall, the use of classic AEDs 
(95.9%) versus newer AEDs (82.19%) did not differ substantially. See Table 3. 
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Table 3 
Medication Usage  
______________________________________________________________________________ 
Frequency Count       n   % 
______________________________________________________________________________ 
 
Classic AEDs 
 
Carbamazepine      17   23.2 
 Clonazepam       3   4.1 
Diastat        21   28.8 
 Diazepam       2   2.7 
 Lorazepam       1   1.4 
 Phenobarbital       1   1.4 
 Phenytoin       7   9.6 
 Primidone       2   2.7 
 Valproic Acid       16   21.91 
Newer AEDs 
Gabapentin       1   1.4 
 Lamotrigine       24   32.9 
 Levetiracetam       10   13.7 
 Oxcarbazepine      5   6.9 
 Pregabalin       13   17.8 
 Topiramate       2   2.7  
 Zonisamide       5   6.9 
______________________________________________________________________________ 
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Measures 
 The Scale for the Evaluation and Identification of Seizures, Epilepsy, and 
Anticonvulsant Side Effects B (SEIZES-B). The SEIZES-B is a 52-item informant based 
instrument designed to measure SE specific to AED use in adults with ID and epilepsy. 
According to symptom severity, the informant rates items on a four-point Likert-type scale. The 
scale addresses the following topics which map onto 14 subscales that cover features of adverse 
SE from AED use: 1) Hematological Disturbances, 2) Electrolyte Disturbances, 3) Hepatic 
Disturbances, 4) Weight Disturbances, 5) Respiratory Disturbances, 6) Gastric Disturbances, 7) 
Dermatological Changes, 8) Hair Changes, 9) Gait Disturbance, 10) Tremor, 11) Sedation, 12) 
Affective disturbances (e.g., depression, tension/agitation anger/hostility), 13) Cognitive 
disturbances (e.g., decreased concentration and attention), and 14) Drug-related Dizziness (e.g., 
gait/movement disturbances). 
Symptom severity is rated as follows: a score of ‘0’ indicates no disturbance; a score of 
‘1’ indicates mild problems; a score of ‘2’ indicates moderate problems; whereas a score of ‘3’ 
indicates impairment in everyday functioning. Only one item from each subscale may be 
endorsed since items are rated on a continuum of increasing severity, with the exception of the 
following four subscales; 1) Gastric Disturbances, 2) Dermatological Disturbances, 3) Hair 
Changes, and 4) Sedation. These four subscales may have more than one item endorsed since 
multiple symptoms may be experienced. For example, in the gastric subscale, endorsement of 
item 19a, “Vomiting shortly after medication is given” may be experienced concurrently with 
endorsement of item 19b, “Vomiting throughout the day”. The endorsement of item 19a would 
yield a score of ‘2’ and endorsement of item 19b would yield a score of ‘3’. Therefore, the total 
item score for the gastric subscale would equal ‘5’. 
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The total score for each endorsed item is recorded in the corresponding numbered item 
space on Section B of the SEIZES-B scoring sheet. The number representing the total item score 
for each subscale is then circled on the scoring scale located above the individual item 
endorsement section and yield s a SEIZES-B profile. 
Direct Observation Method. Direct observations of behavior were completed 
using the PDC Nursing Assessment Form. The PDC Nursing Assessment Form covers 15 
physiological and psychosocial domains designed to closely monitor each patient. The PDC 
epileptologist and neurologists do not typically complete the Nursing Assessment Form. A 
registered nurse, with a background in neurology and psychopharmacology, completes the form 
after each neurology clinic visit. The assessment takes approximately 10 minutes to complete. 
The 15 domains include: 1) Vital Signs, 2) Level of Consciousness/Cognition, 3) Reaction to 
Stimulus (e.g., change in response to stimuli, extremity movement, general withdrawal, tremor), 
4) Psychosocial (e.g., cooperation, restless/anxious, irritable, hostile/uncooperative), 5) Eyes, 
Nose, Throat, Sleep Patterns, Rest Patterns, 6) Cardiovascular (e.g., apical pulse, radial pulse, 
pedal pulse), 7) Respiratory (e.g., breath sounds, character of respirations, muscular 
contractions/reactions, cough sputum), 8) Gastrointestinal (e.g., bowel sounds, abdomen), 9) 
Bowel (e.g., stools, color of stools), 10) Renal Appearance, 11) Musculoskeletal (e.g., 
locomotion, balance, edema), 12) Skin (e.g., color, temperature, turgor, condition), 13) Dental 
(e.g., oral hygiene rating), 14) Reproductive System (e.g., masses, dimpling, discharge), and 15) 
Seizures (e.g., activity, acute episode, post-ictal state, VNS, any changes in seizure type, 
frequency, and duration). Spaces are provided next to each domain to record an absence or 
presence of symptoms. A blank box indicates an absence of symptoms whereas a checkmark in 
the box indicates the presence of symptoms. 
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 Procedure 
Participants were seen at the PDC neurology clinic each week for a period of two months.  
Prior to each visit, the nurse and epileptologist were given the PDC Nursing Assessment Forms. 
These forms were attached to the participant’s medical chart. The nurse and epileptologist were 
instructed to directly observe the participant and complete the form independently for those that 
attended clinic. After the forms were completed, a list of participants that attended clinic that 
week was complied. The SEIZES-B was then administered for those participants who came into 
clinic that week. This control measure was taken in order to avoid time-order confounding 
effects.  
Administration of the SEIZES-B was conducted by a bachelors-level clinical psychology 
graduate student. The graduate student served as the interviewer.  The interviewer was trained 
specifically in the administration and scoring of the SEIZES-B before data collection began. 
Interviews took place in a quiet area of the participants’ homes and took approximately 10 
minutes to complete. Direct-care staff members who had known the participant for at least six 
months prior to the study served as informants. Each item was read to the direct-care staff 
members verbatim. Upon completion of the item, the interviewer instructed the direct-care staff 
to provide a rating. Information from the first four subscales of the SEIZES-B was collected 
from the participants’ medical records by the interviewer. However, this information was not 
included in the analysis. 
In order to estimate convergent validity, eight subscales of the SEIZES-B were compared 
to the corresponding items of the PDC Nursing Assessment Form. Subscales from the SEIZES-B 
that corresponded with the domains from the Nursing Assessment Form included: 1) Respiratory 
Disturbances, 2) Gastric Disturbances, 3) Dermatological Disturbances, 4) Gait Disturbances, 5) 
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Tremor, 6) Sedation, 7) Affective Disturbances, and 8) Cognitive Disturbances. Items from the 
PDC Nursing Assessment Form that did not overlap or could not be observed during the clinic 
visit with the SEIZES-B were not utilized in the comparisons (e.g., Hair Changes, Drug Related 
Dizziness, Sleep and Rest Patterns). 
Results 
 Interrater Reliability of the Direct Observation 
Interrater reliability of the direct observation using the PDC Nursing Assessment Form 
was calculated using Cohen’s kappa correlation coefficient (κ) in order to measure agreement 
between dichotomous variables (presence versus absence of symptoms) while removing chance 
agreement (Hinkle, Wiersma, & Jurs, 1998). This was used to assess whether the nurse and 
epileptologist’s ratings were consistent between observers. Results revealed that the highest 
individual item kappa correlation was κ = .53, p<.05 for Alert/Awake. However, overall, the 
majority of the items reflected low positive correlations (Hinkle, Wiersma, & Jurs, 1998). For 
example, 5 out of the 14 correlations fell below κ = .00. In addition, for a number of items no 
statistics could be computed because the variable was a constant (e.g., shallow breathing, deep 
breathing, emesis, rash, and excoriated skin). The individual item interrater reliability of the 
direct observation is shown in Table 4. 
Table 4 
Interrater Reliability of the Direct Observation 
______________________________________________________________________________ 
Domain       κ 
__________________________________________________________________________________ 
 
Respiratory 
 
Regular Respiration      -.02 
(table continued) 
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(table continued) 
Gastrointestinal 
Guarding      -.01 
Skin 
 Normal Color Skin     -.02 
 
Pale Color Skin     .02 
 
Musculoskeletal 
 
Gait Steady       .44 
 
Change in Gait/Balance    .31 
 
Reaction to Stimulus 
 
 Intermittent Tremor     -.06 
 
Frequent/Constant Tremor    .25 
 
Psychosocial 
 
Irritable      .48 
 
Hostile/Uncooperative    .25 
 
Levels of Consciousness/Cognition 
 
Alert/Awake      .53 
 
Sedated/Drowsy     .30 
 
Lethargic      .25 
 
Change in Cognitive Functioning   -.01 
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Convergent Validity of the SEIZES-B 
Concordance between the SEIZES-B and direct observation were calculated using 
Pearson-product moment correlation coefficients (Tabachnick & Fidell, 2001). The results of the 
correlational analyses were not statistically significant for five of the following domains: Gastric 
Disturbances, Dermatological Disturbances, Tremor, Affective Disturbances, and Cognitive 
Disturbances. The correlation coefficients of the individual items ranged from -.06 for tremor, to 
.97 for Gait Disturbance. However, some of the participants were non-ambulatory; therefore this 
item was only calculated for a subset of the sample. Concordance between items of the SEIZES-
B and direct observation yielded a very high positive correlation for Gait Disturbance, r =.97, 
p<.001 and low positive correlation for Sedation, r =.26, p<.05. Most of the correlation 
coefficients could be classified as having low positive to little if any clinical significance 
(Hinkle, Wiersma, & Jurs, 1998). No statistics were available for Respiratory Disturbance 
because the variable on the PDC Nursing Assessment Form was a constant. Concordance rates 
for the SEIZES-B and direct observation are presented in Table 5. 
Table 5 
Corresponding Total Subscale Scores of the SEIZES-B and Direct Observation 
 
______________________________________________________________________________ 
 
SEIZES-B    Nursing Assessment Form     r  
______________________________________________________________________________ 
      
Respiratory Disturbance  Respiratory      -- 
 
Gastric Disturbances    Gastrointestinal     -.02 
 
Dermatological Disturbances  Skin       -.03 
Gait Disturbances    Musculoskeletal     .97*** 
(table continued) 
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(table continued) 
Tremor     Reaction to Stimulus     -.06 
Sedation     Level of Consciousness/Cognition   .26* 
  
Affective Disturbances  Psychosocial      .21  
 
Cognitive Disturbances  Level of Consciousness/Cognition   -.01 
______________________________________________________________________________ 
-- unable to calculate due to lack of variance 
*** p < .001 
*p < .05 
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STUDY TWO 
Rationale 
The purpose of this study was to investigate differences in the baseline level of 
symptomatology across individuals with ID. Three groups, comprised of those with epilepsy 
taking AEDs, those with a diagnosis of epilepsy not taking AEDs, and those without epilepsy 
taking antipsychotic medications were compared. Individuals without epilepsy taking 
antipsychotic medications served as the control group to determine if significant differences in 
the baseline level of such symptoms existed. Based on the available research (Alvarez, Besag, & 
Iivanainen, 1998; Brodie, 2001; Ettinger, Barr, & Solomon, 2001; Gates, 2000), it was 
hypothesized that those with epilepsy taking AEDs would have higher SE ratings than those not 
taking AEDs and those taking antipsychotic medications because the SEIZES-B was developed 
to assess SE specific to AED use. The relationship between the baseline level of SE symptoms in 
those taking AEDs, non-AEDs, and anti-psychotics has not been researched in the literature.  
Following the comparison across the three groups for overall SE profiles, a series of item 
correlation coefficients within ten subscales of the SEIZES-B was conducted. This analysis was 
exploratory and indicated whether a relationship existed between specific items of the SEIZES-B 
across the designated groups.  
Method 
 Participants 
Participants were recruited from PDC in central Louisiana. Individuals participating in 
this study were those with a diagnosis of ID.  
A power analysis was conducted to determine the sample size of the groups required for 
the present study. Using GPOWER (Faul & Erdfelder, 1992) with a predetermined level of 
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significance set at .05 (Cohen, 1965; 1988), it was determined that a total sample of 159 
participants was required for an ANOVA with three groups for a medium effect size (.5). The 
present study only had 15 participants in each group, with a total sample size of 45. While this 
small sample size serves as a limitation of this study, the study remains important given the 
importance of this topic.  
Three groups of individuals with ID participated in this study. They included individuals 
with epilepsy taking AEDs (n = 15), individuals with a diagnosis of epilepsy not taking AEDs (n 
= 15), and individuals without epilepsy taking antipsychotic medications (n = 15). Participants 
were matched across groups for age (within 10 years), gender, race, level of ID, seizure type 
(where appropriate), and medication type to prevent confounding effects these variables might 
produce prior to data collection. Categorical variables like gender, race, level of ID, seizure type, 
and number of psychotropic medications, were compared using chi-square analysis. Based on 
these analyses, there were no significant differences in these variables. 
Age, a continuous variable, was compared using a one-way ANOVA. Based on this 
analysis, there were no significant differences in age. Participants’ ages ranged from 26 to 87 
years, with the average age of 52 years. There were 34 males and 11 females with mild (n = 0), 
moderate (n = 7), severe (n = 12), profound (n = 25), and unspecified (n = 1) ID. The majority of 
the participants were Caucasian (n = 33) and a smaller sub-sample were African American (n = 
12). Demographic information is presented in Table 6.  
Diagnosis of epilepsy was made by a consulting neurologist who reviewed patient 
medical histories prior to data collection. Classification of seizure type, determined by the 
neurologist, was based on ILEA criteria, clinical description of seizure activity, EEG pattern, and 
additional medical information. These diagnoses were noted during the chart review. 
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Table 6 
Demographic Characteristics of Groups 
 
______________________________________________________________________________ 
 
Characteristic   AED (n = 15)  Non-AED (n = 15) Control (n = 15) 
______________________________________________________________________________ 
Age     
0-21     0 (0%)   0 (0%)   0 (0%) 
22-45    7 (46.7%)   3 (20.0%)  7 (46.7%) 
46-65    6 (40.0%)  9 (60%)  5 (33.3%) 
66+    5 (33.3%)  3 (20.0%)  3 (20.0%) 
Gender 
Female   11 (73.3%)  11 (73.3%)  11 (73.3%) 
Male    4 (26.7%)  4 (26.7%)  4 (26.7%) 
Race 
Caucasian   11 (73.3%)  11 (73.3%)  11 (73.3%) 
African American   4 (26.7%)   4 (26.7%)   4 (26.7%) 
Level of ID 
Moderate   2 (13.3%)   3 (20.0%)  2 (13.3%) 
Severe    4 (26.7%)   4 (26.7%)   4 (26.7%) 
Profound   9 (60.0%)  7 (46.7%)  9 (60.0%) 
Unspecified   0 (0%)   1 (6.7%)  0 (0%) 
______________________________________________________________________________ 
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Of the 30 participants with ID and a diagnosis of epilepsy (AED and non-AED group), 
there were four seizure types noted in this sample. The majority of the participants had 
generalized epilepsy (n = 18), eight had partial epilepsy (v = 3), five out of those eight evolving 
into secondary generalized seizures (n = 5), and Epilepsy NOS (n = 4).  
Differences in medication may have an impact on the presence and severity of symptoms. 
Current medications were noted during the participant’s chart review. All participants in the 
AED and control group were on medications. In the AED group, it was found that 73.3% were 
on one AED, while 20% were taking two AEDs, and 6.7% were taking three AEDs. In the non-
AED group, none of the participants were taking psychotropic medications. In the control group, 
the majority of participants (93.3%) were only on one psychotropic medication, while only one 
participant was on two (6.7%).  
Games-Howell post hoc analyses were employed because equal variances were not 
assumed between groups (Hinkle, Wiersma, & Jurs, 1998). According to the post hoc analyses, 
no significant differences between the three groups on age, visual impairments, hearing 
impairments, and verbal ability (verbal or non- verbal) were identified. Seizure type between the 
AED group and non-AED did not significantly differ. However, significant differences were 
found in ambulation and medication usage among the three groups. That is, significantly more 
participants in the control group were ambulatory (93.3%) than in the AED group (46.7%), F(2, 
42) = 5.15, p = .014. In addition, a significant difference was found in medication usage among 
the three groups, F(2, 42) = 21.10, p = .00. That is, significantly more participants in the AED 
group (p = .00) and control group (p = .00) were taking medications than the non-AED group (p 
= .00). However, differences in the amount of medication taken between the AED group and 
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control group was non-significant (p = .29). Table 7 shows the frequency of medication usage 
among the three groups at the time of the chart review.  
Table 7 
Medication Usage of the Groups 
_____________________________________________________________________________________________ 
Medication Class     Frequency of Usage    
                          
AED   Non-AED  Control 
     (n = 15)  (n = 15)  (n = 15) 
Classic AEDs        
Carbamazepine  2   0   0 
Diastat    2   0   0 
Phenytoin   5   0   0 
 Valproic Acid   4   0   0   
Newer AEDs       
 Lamotrigine   5   0   0  
 Zonisamide   1   0   0 
Anti-psychotics 
Aripiprazole   0   0   3 
Olanzapine   0   0   5 
Quitiapine   0   0   2 
Risperidone   0   0   4 
Thioridazine   0   0   1 
Anxiolitic 
Propanolol   0   0   1 
______________________________________________________________________________ 
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 Measures 
The SEIZES-B, as previously discussed in Study One, is a 52-item informant based scale 
developed for use with adults with ID and epilepsy.  
 Procedure 
 The SEIZES-B was administered to direct-care staff members that had known the 
participant for a minimum of six months prior to the study. A bachelors-level clinical psychology 
graduate student served as the interviewer. Information from the first four subscales of the 
SEIZES-B in the AED group was collected from the individual’s chart or medical records by the 
interviewer. However, this information was not utilized in the comparison. Interviews were 
conducted in accordance with the SEIZES-B manual specifications. All data was collected in the 
same two-month period to prevent confounding effects of time. 
 Following the comparison of the three groups on SE profiles, a series of item correlation 
coefficients were conducted for the following ten subscales from the SEIZES-B: 1) Respiratory 
Disturbance, 2) Gastric Disturbance, 3) Dermatological Disturbance, 4) Hair Changes, 5) Gait 
Disturbance, 6) Tremor, 7) Sedation, 8) Affective Disturbances, and 9) Cognitive Disturbance, 
and, 10) Drug-Related Dizziness. 
Results 
Total scores derived from the SEIZES-B were analyzed across the three diagnostic 
groups (AEDs, non-AEDS, control) using a one-way Analysis of Variance (ANOVA). 
Differences across the nine of the ten subscales of the SEIZES-B were all non-significant. 
However, a significant difference was found across the Hair Changes subscale F(2, 42) = 3.50, p 
= .03. With Games-Howell post hoc analyses, no significant difference was found between the 
AED group and control group (p = .18). Results are displayed in Table 8. 
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Table 8 
Means, Standard Deviations, and ANOVA for SEIZES-B Subscale Totals 
______________________________________________________________________________ 
                AED             Non-AED     Control       ANOVA 
  Variable       M         SD          M           SD        M        SD         F(2,42)     p 
______________________________________________________________________________ 
 
Respiratory Disturbance .33  .90 .00 .00 .00 .00    2.05 .14        
Gastric Disturbance .40 .91 .27 .79 .00 .00 1.27 .29 
Dermatological Disturbance .33 .61 .40 .63 .21 .41  .49 .61 
Hair Changes .60  1.24  .00  .00  .00  .00  3.50       .03* 
Gait Disturbance .40 .91 .13 .51 .20 .41 .68 .51 
Tremor .13 .35 .00 .00 .00 .00 2.15 .12 
Sedation .27 .70 .27 .70 .13 .51 .21 .81 
Affective Disturbance .20 .56 .13 .51 .20 .56 .07 .92 
Cognitive Disturbance .00 .00 .07 .25 .13 .51 .60 .55 
Drug-Related Dizziness .07 .2 5 .00 .0 0 .00 .00 1.00 .37 
*p < .05 
 
After comparing the total subscale scores of the SEIZES-B across the three groups, item 
correlation coefficients were calculated using a matrix of Pearson product-moment correlation 
coefficient. Each item within the ten subscales of the SEIZES-B was compared across the three 
groups. Since this analysis was exploratory in nature, a two-tailed test of significance was set 
because the direction of the relationship was unknown. Based on this analysis, six of the ten 
subscales contained items that were significant in the AED group.  
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In the AED group, very high positive correlations were observed for vomiting shortly 
after medication is given and unsteady wide based gait, r = 1.0, p<.01, vomiting shortly after 
medication is given and transient dizziness, r = 1.0, p<.01, vomiting throughout the day and 
transient dizziness, r = 1.0, p<.01, can only walk with assistance and some mood change; no 
interference with daily activities, r = 1.0, p<.01, and mood changes, interference with some 
activities and unsteady wide based gait, r = 1.0, p<.01. In addition, the non-AED group had 
moderate to very high positive correlations. The control group had two moderately high 
correlation coefficients. Overall, the majority of the correlation coefficients were in the low to 
moderate range. Only significant correlations and are presented in Table 9. 
Table 9 
Pearson Product-Moment Correlation Coefficient for SEIZES-B Items Across Groups 
______________________________________________________________________________ 
Subscale and Item      Item    r  
______________________________________________________________________________ 
AED Group 
Respiratory Disturbances   
Shortness of breath    Slow, unsteady gait    .48**   
 Labored Breathing   Intermittent tremor    .63** 
Gastric Disturbances 
 
Vomiting shortly after   Unsteady, wide based gait   1.0** 
medication is given  
 
Vomiting shortly after   Intermittent tremor    .68** 
medication is given  
 
Vomiting shortly after   Some mood changes;   .68** 
medication is given    no interference with tasks 
 
(table continued) 
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 (table continued) 
Vomiting shortly after   Transient dizziness    1.0** 
medication is given  
 
Vomiting throughout    Transient dizziness    1.0** 
the day    
 
Vomiting throughout    Skin sensitive to light   .68** 
the day 
Vomiting throughout    Hard to awaken, occasionally  .68** 
the day    sleeps during the day 
Dermatological Disturbance 
Rash consisting of red  Hard to awaken, occasionally  .65** 
discolored patches   sleeps during the day    
Rash consisting of red  Difficult to stay awake    .68** 
discolored patches   especially during the day 
Gait Disturbances  
Can only walk with    Mood changes; interfere   1.0** 
assistance     with some daily activities   
Tremor 
Intermittent Tremor    Unsteady wide based gait   .68** 
Intermittent Tremor   Transient dizziness    .68** 
Frequent or constant tremor  Hard to awaken, occasionally  .68** 
sleeps during the day   
Sedation 
Some mood changes;    Unsteady wide based gait   .68** 
no interference with activities 
 
Some mood changes;    Transient dizziness    .68** 
no interference with activities 
(table continued) 
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(table continued) 
 
Mood changes; interference   Unsteady wide based gait   1.0** 
with some activities 
 
Non-AED Group 
Dermatological Disturbance 
Skin sensitive to light as  Gastric distress as evidenced   .68** 
evidenced by burning easily  by doubling over 
 
Gastric Disturbances 
 
Vomiting throughout    Rash consisting of red  .62** 
the day    discolored patches 
Vomiting throughout    Difficult to stay awake  .68** 
the day    especially during the day 
Dermatological Disturbance 
 
Rash consisting of red   Unsteady wide based gait   .68** 
discolored patches   
Affective Disturbance 
Some mood changes; no  Rash consisting of red   .68**   
interference with activities  discolored patches 
Mood changes; interference   Rash consisting of red   .68**   
with some activities   discolored patches 
 
Cognitive Disturbance 
Decline in attention or  Rash consisting of red   .68** 
 concentration but doesn’t interfere     discolored patches 
  
Gait Disturbances  
Unsteady wide based gait   Mood changes interference   1.0** 
     with some activities   
(table continued) 
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(table continued) 
 
Unsteady wide-based gait   Decline in attention or   1.0*  
Concentration but doesn’t interfere     
Sedation     
Difficult to stay awake  Some mood change; no  1.0* 
especially during the day  interference with activities 
 
Difficult to stay awake  Frequent tremor    .68** 
especially during the day 
Control Group 
Sedation 
Difficult to stay awake  Skin sensitive to light   .54* 
especially during the day 
Affective Disturbance 
Mood changes inferences with  Marked impairment of activities  .68** 
some activities   significant confusion 
_____________________________________________________________________________ 
** p < .01 
* p < .05 
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GENERAL DISCUSSION 
 The purpose of the present study was two-fold. In Study One, the psychometric 
properties of the SEIZES-B were investigated. This was achieved by evaluating the interrater 
reliability of direct observations using the PDC Nursing Assessment Form. Direct observations 
were completed by two informants, a registered nurse and licensed epileptologist. This 
comparison was examined to determine if the nurse and epileptologist’s ratings were consistent. 
Then, the convergent validity of the SEIZES-B was examined. The SEIZES-B was compared to 
direct observations of individuals at the PDC neurology clinic using the Nursing Assessment 
Form. In Study Two, differences in the baseline level of SE profiles were evaluated in three 
groups with individuals with ID. These three groups were comprised of individuals with epilepsy 
taking AEDs, individuals with a diagnosis of epilepsy not taking AEDs, and individuals without 
epilepsy taking antipsychotic medications. 
Assessing the interrater reliability of the direct observation was first examined. This step 
was chosen to demonstrate the consistency and dependability of the instrument (Mitchell, 1979). 
Overall, the level of agreement for the majority of the items reflected low positive correlations. 
They ranged from poor for Intermittent Tremor (κ = -0.06), to fair for Alert/Awake (κ = 0.53) at 
the p<.05 level. For the remaining items, all other correlations were considered poor.  
Although the direct observational data did not reveal statistical significance, the Nursing 
Assessment Form has clinical utility because any symptom endorsement (e.g., tremor, sedation) 
alerts the PDC medical staff that monitoring symptoms in an individual may be necessary and 
that medication changes may be appropriate. While it was expected that interrater reliability 
would be high between the nurse and epileptologist, given their level of education and 
experience, it is unclear why concordance rates were not higher.  
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However, before the study began, there was initial resistance from the epileptologist to 
complete direct observation ratings. The epileptologist posited time as a factor. In the research 
literature, it has been recognized that physicians often lack the time or motivation to accurately 
complete rating forms (e.g., symptom checklist, surveys, and questionnaires) (Chappell & 
Smithson, 1997). For example, Traynor and his colleagues (1993) found that researchers’ request 
for physicians to assist in completing surveys was considered an additional demand placed on 
their already busy lives. In addition, Thom, Lee, Dhillon, Dunne, and Plant (2000) found that 
physicians sited lack of interest in epilepsy as reasons for declining to participate in research. 
Perhaps the lack of concordance between the two observers occurred because of differences in 
temperament or differences among interpretations of items on the Nursing Assessment Form. 
The second goal of Study One was to examine the convergent validity of the SEIZES-B 
by comparing the SEIZES-B to direct observations using the Nursing Assessment Form. An 
extensive review of the literature revealed a lack of standardized measures of assessing SE in the 
institutionalized ID population. However, interrater reliability (r = .72) and test-retest reliability 
(r = .63) using direct care staff as informants demonstrated moderately high reliability 
coefficients. According to Campbell and Fiske (1959), both reliability and validity concepts 
require that agreement between measures be demonstrated. Thus, it was essential that the 
comparison measure for the SEIZES-B items was based on observable data and was verified 
with interrater reliability. This comparison provided an estimate of convergent validity to show 
that the instrument accurately measured SE of AEDs. It was hypothesized that the SEIZES-B 
would have good convergent validity with the epileptologist’s ratings from the Nursing 
Assessment Form because both instruments purported to measure similar constructs, and was 
designed specifically for individuals with ID and epilepsy.  
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The results revealed a statistically significant high positive correlation between the 
SEIZES-B and direct observation for Gait Disturbance, r = .97, p<.001. According to Cicchetti 
(1994), .97 is classified as an excellent level of clinical significance. In addition, a statistically 
low positive correlation was found for Sedation, r = .26, p<.05. However, the range of reliability 
coefficients for the remaining items was -.02 to .21. Furthermore, a floor effect observed for the 
following domains: Respiratory Disturbance, Hair Changes, Tremor, and Drug-Related 
Dizziness.  
Several possible reasons why concordance was poor across the two instruments are 
offered. First, education level and training between direct-care staff in residential facilities may 
differ significantly. As a result, some individuals may lack training to delineate possible 
symptoms of drug SE from comorbid medical conditions (e.g., cerebral palsy, movement 
disorders, etc.). It is also possible that direct care staff lack understanding of the specific 
construct being measured despite efforts of scale developers to eliminate unclear questions 
(Cronbach & Meehl, 1955; DeVellis, 1991). However, given the importance of this topic, 
education and training direct care staff to detect SE symptoms may be warranted and may help 
them to detect SE symptoms.  
The lack of convergence between direct care staff and the direct observation question the 
appropriateness of the SEIZES-B when direct care staff is used as raters. According to Mitchell 
(1979), although indirect measures can yield valuable information, they are usually not as 
reliable as direct observation measures. 
Another possible reason for the low convergence may be related to different 
administration times of the two instruments. Although the SEIZES-B was administered one-to-
two weeks after participants attended neurology clinic to prevent confounding effects of time, 
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certain behaviors (e.g., vomiting shortly after medication is given) may have occurred in one 
setting (e.g., home) and not the other (e.g., neurology clinic). Due to shift changes and 
designated appointments times at clinic, direct care staff and medical staff may not witness a 
phenomenon and would be subsequently unable to endorse an item on either instrument.  
Despite the overall lack of convergence of the SEIZES-B and direct observation, gait 
disturbance and sedation are consistently identified in the literature as common SE of AEDs 
(Harbord, 2000; Kustra et al., 2005; Stefan & Feuerstein, in press). While the interrater reliability 
for Gait Disturbance on the Nursing Assessment Form was r = .33, high convergence of this 
subscale on the SEIZES-B suggests its usefulness in identifying possible SE in combination with 
direct observations. 
The second objective of the present study was to examine group differences of SE 
profiles in three groups. In Study Two, 15 participants were compared across three groups (AED, 
non-AED use, and control) on SE profiles of the SEIZES-B. Group membership was the 
independent variable and SEIZES-B total scores served as the dependent variable. A total of 45 
participants were included in this study. A chi-square analysis and ANOVA revealed that the 
groups did not differ significantly on the variables of age, gender, level of ID, seizure type, and 
medication type. 
 A one-way ANOVA revealed a statistically significant difference on the Hair Changes 
subscale. However, no other statistical differences were found. A floor effect was observed for 
the non-AED group and control group on the following subscales: Respiratory Disturbance, Hair 
Changes, Tremor, and Drug-Related Dizziness. Games-Howell post hoc analysis was conducted 
for Hair Changes. This statistic was chosen because the homogeneity of variance assumption had 
been violated (Hinkle, Wiersma, & Jurs, 1998). However, no significant difference was detected 
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between the AED group and control group (p = .18). In the medical literature, hirsutism has been 
observed as a SE of phenytoin use (Buchanan, 1992; Pellock, 2002). Additionally, alopecia has 
been observed as a SE of valproic acid use (Buchanan, 1992; Gates, 2000). Despite the fact that 
the data did not reveal statistically significant differences, the endorsement of one SE symptom 
may provide useful in making recommendations for titration, alternative drug usage, or 
discontinuance. 
 In Study Two, since the sample consisted of a small number of participants in each group 
and a floor effect was observed, a power analysis was conducted to determine whether possible 
non-significance findings may have contributed to low power. It was determined a sample of 158 
participants would be optimal to achieve a power of .80, using a medium effect size (.05). 
Although a much larger sample size would have been ideal, it was impossible to attain due to 
exclusionary criteria and matching practices utilized in this study. Regardless, a larger sample 
may have lead to the detection of more significant differences across the groups.      
 Lastly, a series of individual item correlations were examined in order to examine if there 
was a relationship between certain SE symptoms across the three groups. Based on the analyses, 
all three groups showed low to very high positive correlations among certain items. Because the 
ten subscales of the SEIZES-B contained heterogeneous symptoms, low-to-high correlations 
were not expected. Several subscales, (e.g., Gastric Disturbance, Gait Disturbance, and Sedation) 
showed perfect positive correlations with other constructs. The relationship between these 
various constructs warrants a more thorough investigation of these symptoms before making any 
meaningful interpretation of the endorsed symptom.  
The results of the current study extended research on SE of AEDs in the institutionalized 
ID population. This study represents the first to examine the convergent validity of the SEIZES-
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B and interrater reliability of direct observations. While the individual interrater reliability 
coefficient for Gait Disturbance on the SEIZES-B is considered high by research and clinical 
standards (Cicchetti, 1994; Mitchell, 1979), the convergent validity of the SEIZES-B and direct 
observation were poor. Although it is disappointing that the current study did not establish 
overall high reliability or convergent validity, the psychometric properties of the two instruments 
provided information that was previously unavailable. 
Even though no statistical differences were detected across groups on SE profiles, subtle 
differences in symptomatology are still a major issue in seizure management. As stated earlier, in 
individuals with ID, assessments and monitoring of SE are based on informant-based rating 
scales, changes in observable behaviors, and laboratory monitoring. Based on the results of this 
study, it is clear that informant-based ratings scales and direct observation alone cannot replace 
current assessment and management practices. 
Continued efforts are being made to improve the pharmacological properties of available 
AEDs by developing newer AEDs with fewer interactions and untoward SE (Brodie, 1995). For 
example, pregabalin is a novel AED used for neuropathic pain, as an adjunct therapy for partial 
seizures, and in generalized anxiety disorder (Hamandi & Sander, 2006). It was designed as a 
more potent successor to gabapentin (Sills, 2006), and received U.S. Food and Drug 
Administration approval for use in treating epilepsy, diabetic neuropathy pain and post-herpetic 
neuralgia pain in June 2005 (Hamandi & Sander, 2006). In Study One, 13 (17.8%) participants 
were taking pregabalin at the time of chart review. Stefan and Feurstein (in press) found that the 
most frequent side effects of pregabalin in controlled studies were dizziness, somnolence, ataxia, 
and weight gain. To date, no research has been conducted to assess the SE of pregabalin in the 
institutionalized ID population. Future research in this area is warranted.  
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 Similar to that of pharmacological interventions for individuals with epilepsy, treatment 
of individuals with psychopathology (e.g., bipolar disorder) usually includes a drug regimen. 
According to Matson, González, Smith, Terlonge, Thorson, and Dixon (2006), who conducted a 
20-year review of the literature, SE of pharmacotherapy treatment often include parkinsonism, 
tardive dyskinesia, akathesia, dystonia, and tremor. Elsewhere in the literature, it has been well 
documented that antipsychotic medications are not free from untoward SE in the institutionalized 
ID population (Lipman, 1970). Therefore, it is unlikely that all of the participants in the control 
group were free from experiencing untoward SE.  An explanation for the floor effect observed in 
the non-AED group and control group could be that direct care staff could not consistently 
identify or recall when symptoms occurred. However, the lack of identified symptoms may have 
been compromised by true or random error (Murphy & Davidshofer, 2001).  
 In the field of ID, treatment of epilepsy and identification and monitoring of SE has been 
proven difficult. Potential differences in observers, direct care staff, limitations of participant 
self-report, and methodological constraints, contribute to the complexity of assessment, 
monitoring, and research investigating drug SE in institutionalized ID populations (Matson, 
Bielecki, Mayville, & Matson, 2003). Nevertheless, it behooves us to continue focusing on adults 
with ID and epilepsy and to study, develop, and improve assessment and monitoring techniques 
of SE. Our ability to improve the psychometrics of SE instruments may improve the quality of 
life in individuals with ID. 
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